查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010045

生物製药市场：2026-2032年全球市场预测（依治疗领域、技术、产品类型、给药途径及通路划分）

Biopharmaceuticals Market by Therapeutic Area, Technology, Product Type, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年生物製药市场价值为6,900.4亿美元，预计到2026年将成长至7,493.3亿美元，复合年增长率为10.10%，到2032年将达到1,3536.4亿美元。

主要市场统计数据
基准年 2025 6900.4亿美元
预计年份：2026年 7493.3亿美元
预测年份 2032 13536.4亿美元
复合年增长率 (%) 10.10%

权威说明指出，科学突破、监管复杂性和商业性需求正在重塑整个生物製药产业的战略重点。

生物製药产业正进入一个技术快速成熟和策略重组的阶段，这主要得益于生物製药、基因疗法以及利用数位技术的患者照护模式的进步。相关人员正在适应一个科学突破与日益严格的监管审查、复杂的供应链以及不断变化的支付方期望相互交织的环境。为此，经营团队正在重新评估其业务组合，投资于生产灵活性，并在学术界、合约研发生产机构（CDMO）和数位医疗服务提供者之间建立新的合作伙伴关係。

本文概述了科学、製造和监管预期方面最重大的变化，这些变化正在重新定义生物製药领域的竞争优势和策略性投资。

该产业正经历变革性的转变，重塑着药物发现、开发和供应各个阶段的竞争优势。首先，治疗方法的多样化正在加速。细胞和基因疗法正从实验阶段迈向商业化阶段，而重组技术和融合瘤方法也在不断改进，製程优化和分析技术不断进步。同时，数位化工具和真实世界数据正日益融入研发和打入市场策略，从而能够采用适应性试验设计，并更有效率地产生核准后证据。

分析检视 2025 年关税调整对生物製程原料和成品生物製药产品的影响将如何改变筹资策略、供应弹性和商业合约。

2025年即将推出的关税和贸易措施等政策将影响生物製药原料和成品，对拥有跨境供应链的企业带来新的营运压力。原料、一次性耗材和某些生物製程设备的进口关税提高，推高了依赖全球采购的企业的生产成本，促使它们寻求供应商多元化并重新审视在地采购策略。因此，企业正在迅速开展供应商风险评估，并优先选择替代供应商以降低供应中断的风险。

将治疗重点、技术平台、通路和给药途径与策略开发和商业化方案联繫起来的全面细分洞察。

详细的细分洞察揭示了治疗重点如何与技术选择、分销偏好和产品类型相契合，从而塑造差异化的开发和市场策略。依治疗领域划分，治疗方法范围涵盖自体免疫疾病（如发炎性肠道疾病、干癣和类风湿性关节炎） ；心血管疾病（包括心臟衰竭、高胆固醇症和高血压）；感染疾病（涵盖抗生素、抗病毒药物和疫苗）；神经病学（重点阿兹海默症、骨髓恶性肿瘤和囊肿纤维化氏症（固体癌学（肿瘤学）。每个临床重点领域都决定了不同的临床开发路径和核准后证据要求。

重点区域观察结果，强调美洲、欧洲、中东和非洲以及亚太地区的法规结构、支付系统和物流如何影响战略规划。

区域趋势影响监管预期、支付系统和营运物流，进而对策略规划和实施产生重大影响。在美洲，市场准入途径是与集中式支付方和区域报销政策进行谈判的综合体现，这需要量身定制的卫生经济学证据和弹性价格设定策略。从供应链角度来看，稳健的低温运输物流和跨境分销紧急时应对计画至关重要，而分散式临床试验模式也日益受到关注，以提高病患招募和留存率。

关键的企业级洞察突显了整合能力、伙伴关係和跨职能人才投资如何创造竞争优势。

企业层面的倡议，尤其是着重于差异化能力、策略伙伴关係和卓越营运的倡议，持续塑造竞争动态。主要企业正在整合其在先进生物製药和基因疗法製造方面的核心能力，同时将一些细分领域的业务外包给专业的合约合作伙伴。此外，他们也正在投资建置数位化平台，整合临床、生产和商业数据，以加快决策速度，并提升产品全生命週期的可追溯性。

为行业领导者提供可操作的建议，优先考虑产品组合重点、製造敏捷性和商业化准备，以将科学创新转化为可持续的竞争优势。

领导企业必须采取果断行动，迅速将研发诚信、生产柔软性和商业性韧性等领域的洞察转化为实际行动。首先，应优先精简产品组合，将投资集中在具有明确临床差异和可行监管路径的适应症和治疗方法。将药物研发重点与可扩展的生产方式结合，将降低下游风险，并实现更可预测的供应计画。同时，应透过认证双源供应商、投资模组化生产设施以及采用可处理多个产品系列的平台技术，来提升生产柔软性。

我们透明且可重复的调查方法，结合了与关键相关人员的访谈、监管审查和情境分析，得出可操作的营运和策略见解。

为确保可靠性和透明度，本分析采用结构化且可重复的调查方法，整合了来自一手和二手研究的发现。一手资料包括对生物製药研发、生产、监管事务和商业部门的高级管理人员以及负责人的定性访谈。二手资料包括监管指导文件、临床和科学文献、行业政策公告以及支持主题趋势和营运影响的上市公司披露资讯。

简洁的结论强调了为什么涵盖科学、製造和取得的整合策略对于将治疗方法创新转化为可持续的患者和商业性成果至关重要。

总之，生物製药产业正处于转折点，科学进步、製造创新和政策趋势在此交汇，既带来机会也带来风险。能够整合跨部门策略，将治疗方法优先顺序与合适的技术平台、稳健的供应链以及符合实际情况的商业模式相结合的机构，将获得最大的长期价值。同样重要的是，需要事先规划，以应对外部压力，例如贸易政策调整和区域监管差异，这些因素可能对产品供应和价格趋势产生重大影响。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物製药市场：依治疗领域划分

  • 自体免疫
    • 发炎性肠道疾病
    • 银屑病
    • 类风湿性关节炎
  • 循环系统
    • 心臟衰竭
    • 高胆固醇症
    • 高血压
  • 感染疾病
    • 抗生素
    • 抗病毒药物
    • 疫苗
  • 神经病学
    • 阿兹海默症
    • 多发性硬化症
    • 帕金森氏症
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固体癌
  • 罕见疾病
    • 囊肿纤维化
    • 血友病
    • 溶小体贮积症

第九章：生物製药市场：依技术划分

  • 细胞培养
    • 哺乳动物
    • 微生物
  • 基因治疗
    • 非病毒载体
    • 病毒载体
  • 融合瘤
  • 重组DNA

第十章：生物製药市场：依产品类型划分

  • 生物相似药
  • 学名药

第十一章：生物製药市场：依给药途径划分

  • 吸入
  • 肌肉内部
  • 静脉
  • 口服
  • 皮下
  • 外用

第十二章 生物製药市场：依通路划分

  • 离线
  • 在线的

第十三章 生物製药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 生物製药市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 生物製药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国生物製药市场

第十七章：中国生物製药市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CSL Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Kyowa Kirin Co. Ltd.
  • Merck & Co. Inc.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
Product Code: MRR-434CCDA05130

The Biopharmaceuticals Market was valued at USD 690.04 billion in 2025 and is projected to grow to USD 749.33 billion in 2026, with a CAGR of 10.10%, reaching USD 1,353.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 690.04 billion
Estimated Year [2026] USD 749.33 billion
Forecast Year [2032] USD 1,353.64 billion
CAGR (%) 10.10%

An authoritative introduction to how scientific breakthroughs, regulatory complexity, and commercial demands are reshaping strategic priorities across the biopharmaceutical sector

The biopharmaceutical landscape has entered a phase of rapid technological maturation and strategic repositioning, driven by advances in biologics, gene therapies, and digital-enabled patient care models. Industry stakeholders are adapting to an environment where scientific breakthroughs meet heightened regulatory scrutiny, complex supply chains, and evolving payer expectations. In response, executives are reevaluating portfolios, investing in manufacturing agility, and forging new collaborations that span academia, contract development and manufacturing, and digital health providers.

Consequently, organizations must balance scientific ambition with operational resilience. Firms that align R&D priorities with scalable manufacturing technologies and that integrate patient-centric distribution channels are better positioned to convert innovation into sustained clinical and commercial impact. From an investor and leadership perspective, the imperative is clear: translate complex scientific advances into reproducible processes, credible regulatory strategies, and robust commercialization plans that reduce time to patient.

A synthesis of the most consequential shifts in science, manufacturing, and regulatory expectations that are redefining competitive advantage and strategic investment in biopharmaceuticals

The sector is experiencing transformative shifts that reconfigure competitive advantages across discovery, development, and delivery. First, modality diversification has accelerated; cell and gene therapies are transitioning from experimental to commercial stages, while recombinant and hybridoma approaches continue to evolve with process optimizations and analytical improvements. At the same time, digital tools and real-world evidence are increasingly integrated into development and market access strategies, enabling adaptive trial designs and more efficient post-approval evidence generation.

Moreover, supply chain resilience and manufacturing agility have moved from operational objectives to strategic imperatives. Companies are investing in flexible cell culture platforms and modular facilities, and they are pursuing decentralized distribution pathways to bring therapies closer to patients. Regulatory frameworks are also adapting, with agencies issuing guidance that supports expedited pathways while demanding rigorous long-term safety monitoring. These combined dynamics call for cross-functional alignment, where R&D, regulatory, manufacturing, and commercial teams converge on shared milestones and risk management approaches.

An analytical review of how 2025 tariff adjustments affecting bioprocessing inputs and finished biologics are altering sourcing strategies, supply resilience, and commercial contracts

Policy actions in 2025 introducing tariffs and trade measures affecting biologics inputs and finished products have introduced new operational pressures for firms with cross-border supply chains. Increased import duties on raw materials, single-use consumables, and certain bioprocessing equipment raise production costs for organizations that rely on globalized procurement, prompting a reassessment of supplier diversification and local sourcing strategies. In turn, companies are conducting rapid supplier risk assessments and prioritizing qualification of alternative vendors to mitigate interruptions.

These tariff-related pressures also influence commercial strategies. Firms evaluating route-to-market decisions face higher landed costs in affected geographies, which can alter pricing negotiations with payers and distributors. As a result, organizations are exploring contractual hedges, localized manufacturing partnerships, and value-based contracting to preserve access and margins. From a strategic perspective, these developments accelerate the shift toward nearshoring and regional manufacturing capacity while emphasizing inventory optimization and scenario planning to preserve continuity of clinical supply and commercial distribution.

Comprehensive segmentation-driven insights that link therapeutic priorities, technology platforms, distribution pathways, and administration routes to strategic development and commercialization choices

Deep segmentation insight reveals where therapeutic priorities align with technology choices, distribution preferences, and product types, shaping differentiated development and go-to-market strategies. When therapies are organized by therapeutic area, the landscape spans autoimmune conditions including inflammatory bowel disease, psoriasis, and rheumatoid arthritis; cardiovascular indications that encompass heart failure, hypercholesterolemia, and hypertension; infectious disease categories covering antibiotics, antivirals, and vaccines; neurology areas focused on Alzheimer's disease, multiple sclerosis, and Parkinson's disease; oncology workstreams addressing hematological malignancies and solid tumors; and rare disease programs targeting cystic fibrosis, hemophilia, and lysosomal storage disorders. These clinical focuses drive distinct clinical development pathways and post-approval evidence needs.

Concurrently, technology segmentation maps onto those clinical priorities. Cell culture platforms, subdivided into mammalian and microbial systems, remain essential for many recombinant biologics, while gene therapy approaches split between viral and nonviral vectors demand specialized manufacturing know-how and long-term safety monitoring. Hybridoma and recombinant DNA techniques continue to underpin monoclonal antibody development and biosimilar production. Distribution channel segmentation differentiates direct-to-patient models and hospital pharmacy fulfillment from online and retail pharmacy pathways, each requiring tailored cold chain, adherence support, and reimbursement navigation. Product type divides into biosimilars and generics, which impose distinct regulatory and commercialization tactics. Route of administration choices-ranging from inhalation and intramuscular to intravenous, oral, subcutaneous, and topical-further inform formulation development, patient adherence programs, and supply logistics. Finally, direct sales, hospital pharmacies, online pharmacies, and retail pharmacies represent overlapping but distinct distribution networks that influence commercial resource allocation and channel-specific patient engagement strategies.

Taken together, these segmentation layers enable more precise portfolio management. By aligning therapeutic ambitions with appropriate technology platforms, distribution routes, and product types, organizations can define clearer clinical development hypotheses, optimize manufacturing investments, and tailor commercialization plans that address payer expectations and patient access dynamics.

Key regional observations highlighting how regulatory frameworks, payer systems, and logistics across the Americas, Europe Middle East & Africa, and Asia-Pacific influence strategic planning

Regional dynamics shape regulatory expectations, payer systems, and operational logistics in ways that materially affect strategic planning and execution. In the Americas, market access pathways are shaped by a mix of centralized payer negotiation and regional reimbursement policies, which requires tailored health economics evidence and flexible pricing approaches. Supply chain considerations emphasize robust cold chain logistics and contingency planning for cross-border distribution, while decentralized clinical trial models are gaining traction to enhance patient recruitment and retention.

In Europe, Middle East & Africa, regulatory harmonization initiatives coexist with heterogeneous reimbursement landscapes, calling for differentiated strategies that incorporate local health technology assessment requirements and region-specific safety monitoring obligations. Companies often adopt phased market entry plans and regionally adapted value dossiers. Meanwhile, the Asia-Pacific region presents a diverse mix of regulatory maturity, manufacturing capability, and rapidly evolving patient access frameworks. Here, partnering with regional contract manufacturers and leveraging local clinical infrastructure can accelerate access, while market-specific pricing and reimbursement strategies remain essential. Across all regions, geopolitical shifts, trade policy, and infrastructure capability interact to influence where companies prioritize manufacturing investment, clinical programs, and commercial launches.

Critical company-level insights emphasizing how capability consolidation, partnerships, and cross-functional talent investments are shaping competitive differentiation

Company-level behavior continues to define competitive dynamics, with an emphasis on differentiated capabilities, strategic partnerships, and operational excellence. Leading organizations are consolidating core capabilities in advanced biologics and gene therapy manufacturing while outsourcing niche activities to specialized contract partners. They are also investing in digital platforms that integrate clinical, manufacturing, and commercial data to accelerate decision-making and improve traceability across product lifecycles.

Strategic alliances and licensing arrangements remain central to expanding pipelines and accessing new geographies. Companies with robust in-house regulatory expertise are better positioned to navigate adaptive approval pathways and to design post-approval evidence programs that support market access. Additionally, there is heightened attention to talent acquisition in bioprocess engineering, regulatory science, and value access functions. Firms that cultivate cross-disciplinary teams can move more efficiently from innovation to scale, reducing operational friction and increasing the likelihood of sustained commercial success.

Actionable recommendations for industry leaders that prioritize portfolio focus, manufacturing agility, and commercial readiness to translate scientific innovation into durable competitive advantage

Leaders must move decisively to convert insight into action across R&D alignment, manufacturing flexibility, and commercial resilience. First, prioritize portfolio rationalization that focuses investments on indications and modalities with clear clinical differentiation and feasible regulatory pathways. Aligning discovery priorities with scalable manufacturing approaches reduces downstream risk and facilitates more predictable supply planning. At the same time, expand manufacturing flexibility by qualifying dual-source suppliers, investing in modular production assets, and adopting platform technologies that can accommodate multiple product families.

Second, strengthen commercial readiness by developing distribution models that match therapy characteristics and patient needs. For therapies requiring specialized handling or administration, design provider engagement programs and patient-support infrastructure that reduce barriers to adoption. Negotiate payer arrangements that leverage robust real-world evidence and value-based contracting to support access. Third, accelerate strategic partnerships with academic centers, contract manufacturers, and digital-health providers to access technical expertise and local market knowledge. Finally, institutionalize scenario-based planning that incorporates policy shifts such as tariffs and trade restrictions so organizations can pivot rapidly while preserving clinical supply and payer relationships.

A transparent and reproducible research methodology combining primary stakeholder interviews, regulatory review, and scenario analysis to derive actionable operational and strategic insights

This analysis synthesizes primary and secondary research inputs with a structured, reproducible methodology to ensure credibility and transparency. Primary inputs include qualitative interviews conducted with senior executives across biopharma research and development, manufacturing, regulatory affairs, and commercial operations, as well as practitioners from contract development and manufacturing organizations and distribution partners. Secondary sources include regulatory guidance documents, clinical and scientific literature, industry policy releases, and public company disclosures that validate thematic trends and operational implications.

Analysts applied a layered approach to data synthesis, combining thematic coding of qualitative interviews with comparative analysis of regulatory and operational frameworks across regions. Scenario analysis was used to evaluate the operational impact of trade policy shifts and supply chain disruptions, and triangulation across multiple sources ensured robustness of the insights. Throughout the process, emphasis was placed on identifying actionable implications rather than producing quantitative estimates, and gaps in public information were noted to guide potential follow-up inquiries and customized client engagements.

A concise conclusion emphasizing why integrated strategies across science, manufacturing, and access are essential to convert therapeutic innovation into sustained patient and commercial outcomes

In conclusion, the biopharmaceutical sector stands at an inflection point where scientific advances, manufacturing innovation, and policy dynamics converge to create both opportunity and risk. Organizations that integrate cross-functional strategies-linking therapeutic prioritization with appropriate technology platforms, resilient supply chains, and context-sensitive commercial models-will capture the greatest long-term value. Equally important is the need to anticipate and plan for external pressures such as trade policy adjustments and regional regulatory divergence, which can materially affect product availability and pricing dynamics.

Therefore, executive teams should commit to deliberate investments in flexible manufacturing, strategic partnerships, and evidence-generation capabilities that support access negotiations. By aligning organizational capabilities with the nuanced requirements of different therapeutic areas, routes of administration, and distribution channels, companies can convert scientific promise into sustainable patient impact and commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopharmaceuticals Market, by Therapeutic Area

  • 8.1. Autoimmune
    • 8.1.1. Inflammatory Bowel Disease
    • 8.1.2. Psoriasis
    • 8.1.3. Rheumatoid Arthritis
  • 8.2. Cardiovascular
    • 8.2.1. Heart Failure
    • 8.2.2. Hypercholesterolemia
    • 8.2.3. Hypertension
  • 8.3. Infectious Disease
    • 8.3.1. Antibiotics
    • 8.3.2. Antivirals
    • 8.3.3. Vaccines
  • 8.4. Neurology
    • 8.4.1. Alzheimers
    • 8.4.2. Multiple Sclerosis
    • 8.4.3. Parkinsons
  • 8.5. Oncology
    • 8.5.1. Hematological Malignancies
    • 8.5.2. Solid Tumors
  • 8.6. Rare Disease
    • 8.6.1. Cystic Fibrosis
    • 8.6.2. Hemophilia
    • 8.6.3. Lysosomal Storage Disorders

9. Biopharmaceuticals Market, by Technology

  • 9.1. Cell Culture
    • 9.1.1. Mammalian
    • 9.1.2. Microbial
  • 9.2. Gene Therapy
    • 9.2.1. Nonviral Vector
    • 9.2.2. Viral Vector
  • 9.3. Hybridoma
  • 9.4. Recombinant Dna

10. Biopharmaceuticals Market, by Product Type

  • 10.1. Biosimilars
  • 10.2. Generics

11. Biopharmaceuticals Market, by Route Of Administration

  • 11.1. Inhalation
  • 11.2. Intramuscular
  • 11.3. Intravenous
  • 11.4. Oral
  • 11.5. Subcutaneous
  • 11.6. Topical

12. Biopharmaceuticals Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Biopharmaceuticals Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopharmaceuticals Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopharmaceuticals Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biopharmaceuticals Market

17. China Biopharmaceuticals Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Biogen Inc.
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. CSL Limited
  • 18.12. Dr. Reddy's Laboratories Ltd.
  • 18.13. Eli Lilly and Company
  • 18.14. Gilead Sciences Inc.
  • 18.15. GlaxoSmithKline plc
  • 18.16. Intas Pharmaceuticals Ltd.
  • 18.17. Johnson & Johnson
  • 18.18. Kyowa Kirin Co. Ltd.
  • 18.19. Merck & Co. Inc.
  • 18.20. Novartis International AG
  • 18.21. Novo Nordisk A/S
  • 18.22. Pfizer Inc.
  • 18.23. Roche Holding AG
  • 18.24. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PARKINSONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PARKINSONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PARKINSONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY LYSOSOMAL STORAGE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MAMMALIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NONVIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NONVIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY NONVIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYBRIDOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYBRIDOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY HYBRIDOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY RECOMBINANT DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. GCC BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. GCC BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 268. GCC BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 269. GCC BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 270. GCC BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. GCC BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. GCC BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 274. GCC BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. GCC BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. GCC BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. GCC BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. G7 BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 309. G7 BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 310. G7 BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 311. G7 BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 312. G7 BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 313. G7 BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. G7 BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. G7 BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 316. G7 BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 317. G7 BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 318. G7 BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 319. G7 BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. G7 BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. G7 BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. NATO BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 323. NATO BIOPHARMACEUTICALS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 324. NATO BIOPHARMACEUTICALS MARKET SIZE, BY AUTOIMMUNE, 2018-2032 (USD MILLION)
  • TABLE 325. NATO BIOPHARMACEUTICALS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 326. NATO BIOPHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 327. NATO BIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 328. NATO BIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. NATO BIOPHARMACEUTICALS MARKET SIZE, BY RARE DISEASE, 2018-2032 (USD MILLION)
  • TABLE 330. NATO BIOPHARMACEUTICALS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. NATO BIOPHARMACEUTICALS MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 332. NATO BIOPHARMACEUTICALS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 333. NATO BIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. NATO BIOPHARMACEUTICALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. NATO BIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 336. GLOBAL BIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES BIOPHARMACEUTICALS MAR